In a report released today, Robert Driscoll from Wedbush maintained a Hold rating on Five Prime Therapeutics (NASDAQ: FPRX), with a price target of $19. The company’s shares closed yesterday at $14.70, close to its 52-week low of $13.91.
According to TipRanks.com, Driscoll is ranked 0 out of 5 stars with an average return of -13.3% and a 33.3% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Paratek Pharmaceuticals, and Achaogen.
The word on The Street in general, suggests a Hold analyst consensus rating for Five Prime Therapeutics with a $19 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $48.87 and a one-year low of $13.91. Currently, Five Prime Therapeutics has an average volume of 335.7K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FPRX in relation to earlier this year. Earlier this month, Aron Marc Knickerbocker, the President & CEO of FPRX bought 1,000 shares for a total of $11,140.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
